Serotonin receptors: Subtypes, functional responses and therapeutic relevance by Saxena, P.R. (Pramod Ranjan)
Pharmac. Thu. Vol. 66, pp. 33%368, 1995 
Pergamon 
0163-7258(94)oooo5-4 
Copyright 0 1995 Elsevier Science Ltd 
Printed in Great Britain. All rights reserved 
0163-7258/95 $29.00 
Specialist Subject Editor: F. MITCHELSON 
SEROTONIN RECEPTORS: 
SUBTYPES, FUNCTIONAL RESPONSES 
AND THERAPEUTIC RELEVANCE 
PRAMOD R. SAXENA 
Department of Pharmacology, Dutch Migraine Research Group and Cardiovascular 
Research Institute C’COEUR”), Fatuity of Medicine and Health Sciences, 
Erasmus University Rotterdam, Post Box 1738, 3000 DR Rotterdam, The Netherlands 
Abstract-Recent, rapid progress in the molecular biology of serotonin (5HT) receptors 
requires conceptual re-thinking with respect to receptor classification. Thus, based on 
operational criteria (agonist and antagonist rank order), as well as transduction mechanisms 
involved and the structure of the receptor protein, the Nomenclature Committee of the Serotonin 
Club has proposed the following classification and nomenclature: the main receptor types 5-HT, 
to S-HT4, recombinant receptors (e.g. 5-ht, to 5-ht7) and ‘orphan’ receptors. The aim of the 
present review is to discuss the events leading to this classification, the criteria for and functional 
responses mediated by various 5-HT receptors, as well as the therapeutic possibilities with 5-HT 
ligands. 
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340 P. R. Saxena 
INTRODUCTION 
Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter in the CNS, but is also present 
in particularly high concentrations in blood platelets and the enterochromaffin cells of 
gastrointestinal mucosa. Though the vasoconstrictor properties of defibrinated blood and blood 
serum were long known (Ludwig and Schmidt, 1868), it was only in 1948 that Page (1958) 
succeeded in isolating a crystalline complex ‘serotonin’ from the blood serum (Rapport et al., 
1948); the active moiety of this complex was found to be 5-HT (Rapport, 1949). In the 1930s 
Erspamer and colleagues became involved in the characterization of ‘enteramine’ from the 
enterochromaffin cells in the gastrointestinal tract (see Erspamer, 1954). Subsequently, 
‘enteramine’ was also identified as 5-HT and the chemical identity of the natural and synthetic 
serotonin was backed by the similarity of pharmacological profile, such as contraction of the sheep 
carotid artery, guinea-pig, mouse and rabbit jejunum, rat and cat uterus and cat nictitating 
membrane, triphasic blood pressure response and antagonism by yohimbine and potentiation by 
cocaine of the sheep carotid artery contraction (Erspamer, 1954; Page, 1958). Thus, the scene was 
set for the characterization of serotonin receptors. 
2. EARLY SEROTONIN RECEPTOR CLASSIFICATIONS 
2.1. Gaddum’s ‘M’ and ‘D’ Serotonin Receptors 
Woolley and Shaw (1953a,b) and Page and McCubbin (1953) reported that the vascular 
responses to serotonin could be antagonized by several drugs including some tryptamine 
derivatives. Caddum (1953) found that the guinea-pig isolated ileum was selectively desensitized 
to serotonin or substance P by high concentrations of these substances, suggesting that the two 
compounds activated different receptor populations. The serotonin-induced contraction of the 
guinea-pig ileum was not affected by drugs such as diphenhydramine, nicotine (high doses), 
hexamethonium or decamethonium, but was partially suppressed by atropine and cocaine, as well 
as by its own repeated administration, at which time the responses to histamine, acetylcholine, 
pilocarpine or nicotine were unaffected (Feldberg and Toh, 1953; Rapport and Koelle, 1953; 
Rocha e Silva et al., 1953). Gaddum and Hameed (1954) postulated that there must be two types 
of receptors on the enteric parasympathetic ganglia, which responded to either serotonin or 
nicotine. It was also reported that the vasoconstrictor effect of serotonin on the rabbit ear artery 
was not much affected by piperoxan, atropine or cocaine, was moderately antagonized by 
dibenamine and gramine, but was potently blocked by lysergide, dihydroergotamine or 
ergotamine. 
A vital step towards characterization of serotonin receptors was undertaken by Gaddum and 
Picarelli (1957), who reported that the serotonin-induced guinea-pig ileum contraction was only 
partially blocked by either morphine or dibenzyline (phenoxybenzamine), but was completely 
antagonized by the combined use of the two compounds. Furthermore, lysergide, 
2-bromolysergide and dihydroergotamine completely antagonized the response to serotonin in 
the morphine-treated ileum, and the same was true for atropine and cocaine in the 
dibenzyline-treated ileum. It was concluded, therefore, that serotonin activated two different types 
of receptors: an ‘M’ serotonin receptor, located on the parasympathetic ganglion and mediating 
acetylcholine release from postganglionic nerve endings, and a ‘D’ serotonin receptor, located on 
smooth muscles and directly contracting the muscle (Fig. 1). However, it may be noted that the 
interference of the contractile effect of serotonin by morphine and atropine was due to the 
inhibition of acetylcholine release (see Saxena, 1970) and its interaction with the muscarinic 
receptor, respectively; only cocaine proved to be a weak ‘M’ serotonin receptor antagonist (see 
Fozard, 1990), while phenoxybenzamine acted as an unspecific antagonist. 
For a long time, no potent and selective antagonist at ‘M’ serotonin receptors was reported, 
but a number of compounds (e.g. cyproheptadine, lysergide, methysergide, pizotifen, mianserin) 
became known as ‘D’ serotonin receptor antagonists. 
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Parasympathetic nerve 
M - ‘M’ serotonin receptor 
D = ‘D’ serotonin receptor 
NR = Nicotinic receptor 
MR - Muscarlnic receptor 





Fig. 1. Graphic illustration of the location of ‘M’ and ‘D’ serotonin receptors inthe guinea-pig 
ileum. 
2.2. No&M and No&D Serotonin Receptors 
Despite the ‘M’ and ‘D’ serotonin receptor classification becoming widely accepted, there were 
some responses to serotonin which could not be placed within this scheme. For example, in the early 
1970s it was reported that the ‘D’ receptor antagonists, mianserin and cyproheptadine, failed to 
antagonize the vasoconstrictor effect of serotonin in the canine external carotid arterial bed (Fig. 2). 
Therefore, it was concluded that the serotonin receptors in the external carotid vascular bed of the 
dog were of a ‘special’ type and could not be categorized as either ‘M’ or ‘D’ type (Saxena et al., 
1971; Saxena, 1972; Saxena and De Vlaam-Schluter, 1974). 
2.3. 5-HT, and 5-HT2 ‘Receptors’ 
Bennett and Aghajanian (1974) reported the first successful radioligand binding study of 
serotonin receptors using D-[3H]lysergide. [3H]serotonin also showed a high affinity, but because 
of discrepancies between the binding of [3H]lysergide and [‘Hlserotonin, a recognition site with 
two different states was suggested (Bennett and Snyder, 1976; Fillion et al., 1978). However, 
further studies with [3H]serotonin, [‘Hlspiperone and [‘Hjlysergide enabled Peroutka and Snyder 
(1979) to suggest the existence of two distinct serotonin ‘receptors’-a 5-HT, ‘receptor’ (high 
nanomolar affinity for serotonin) and a 5-HTz ‘receptor’ (high affinity for spiperone and low 
micromolar affinity for serotonin). Subsequently, Pedigo et al. (1981) reported that the 5-HT, 
binding site could be subdivided into 5-HTIA and 5-HTu, subtypes on the basis of high and low 
affinity, respectively, for spiperone. Soon, 8-OH-DPAT was recognized as a selective ligand for 
the 5-HTIA subtype (Middlemiss and Fozard, 1983). This subdivision of the 5-HT, binding site 
continued into 5-HT,e (Pazos et al., 1984), 5-HT,u (Heuring and Peroutka, 1987), 5-HTIE 
(Leonhardt et al., 1989) and 5-HTkF (Amlaiky et al., 1992; Adham et al., 1993) subtypes; the 
5-HT,u subtype itself also appeared to be heterogeneous (Sumner and Humphrey, 1989). 










Dose (mg/kg, i.v.) 
Fig. 2. Dog external carotid artery vascular bed. Effect of mianserin, methysergide, 
cyproheptadine and ergotamine on the vasoconstrictor response toserotonin. Values below the 
interrupted line (i.e. change more than 100%) mean that serotonin caused vasodilatation instead 
of vasoconstriction. Note that the apparent reversal of the response toserotonin by ergotamine 
may have been due to its strong vasoconstrictor p operty. *Significant 0, < 0.05) change 
compared with parallel administration f saline. Data from Saxena et al. (1971) and Saxena 
(1972). 
3. MODERN SEROTONIN RECEPTOR CLASSIFICATION 
3.1. Development of a Framework 
The need for a uniform terminology for serotonin receptors was apparent, since these receptors 
were being referred to by various names (‘D , ’ ‘M’, 5-HT,, 5-HT2, S,, SZ etc.) (Humphrey, 1983; 
Verdouw et al., 1984). Indeed, it was suggested that the old serotonin receptor classifications “should 
give way to a new classification based on a 5-HTI, 5-HT2, 5-HT, series. . the 5-HT receptors 
subserving arteriolar dilatation, presynaptic inhibition of sympathetic transmission, autoinhibition 
in the brain and possibly constriction of arteriovenous anastomoses, could be termed 5-HT,. The 
receptors mediating vaso- and broncho-constriction and platelet aggregation could be called 5-HT, 
receptors and those mediating ganglionic stimulation, the Bezold-Jarisch reflex and catecholamine 
release in the heart should be designated as 5-HT3 receptors in place of ‘M’ receptors. As there are 
many effects of 5-HT which await classification. . . this series could, if needed, be extended by using 
both numbers and letters (as additional subscripts)” (Verdouw et al., 1984). 
In 1986, a group of scientists formulated criteria for the characterization, and a general framework 
for the nomenclature of serotonin receptors. From the beginning, it was obvious that either of the 
two previous classifications proposed by Gaddum and Picarelli (1957) and Peroutka and Snyder 
(1979) were incomplete, but did complement each other. Therefore, it was decided to build upon these 
two classifications, taking into account rank order and ligand binding affinities of the agonists and 
antagonists, with some consideration of the second messenger systems involved. Thus, serotonin 
receptors were classified into three main categories: 5-HT,-like (corresponding to some ‘D’ receptors 
and 5-HT, binding sites), 5-HTz (corresponding to most ‘D’ receptors and 5-HTz binding sites) and 
5-HT3 (equivalent o ‘M’ receptors) (Bradley et al., 1986). The important criteria for classification 
were: 5-HT,-like receptors-5-carboxamidotryptamine, generally a more potent agonist than 
serotonin, high affinity for the antagonist methiothepin, but not for ketanserin or ICS 205-930 
(tropisetron); 5-HT2 receptors-high affinity for the agonist a-methyl-5-HT and antagonists 
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ketanserin and methiothepin, but not for tropisetron, coupling to phosphatidylinositol turnover; and 
5-HT, receptors-high affinity for the agonist 2-methyl-5-HT and antagonist ropisetron, but not 
for ketanserin or methiothepin, part of cation channels. It was clearly pointed out that the 5-HT&ke 
receptors were heterogeneous and that some serotonin responses, e.g. the tachycardia in the pig 
(Duncker et al., 1985), still defied classification. Shortly thereafter, 5-HT, recognition sites were 
described in the brain (Kilpatrick et al., 1987) and evidence in favour of 5-HT., receptors began to 
emerge (see Saxena, 1986; Born et al., 1988; Dumuis et al., 1988, 1989). 
3.2. Cloning of Serotonin Receptors 
Since the original scheme of serotonin receptor classification was proposed (Bradley et al., 1986) 
an enormous amount of new information on the molecular biology of serotonin receptors has become 
available. Several receptors have now been cloned and expressed in cells, and the amino acid sequence 
and structure of the receptor protein, as well as the gene involved, have been determined. 
Furthermore, using second messenger responses in the host cell, agonists’ and antagonists’ rank order 
of the recombinant serotonin receptors has been compared with that of the native receptors. This 
process has led to identification of several serotonin receptor clones (Table 1). In the case of 5-HT4 
receptors, the clones have two splice variants: a short form with 387 amino acids (5-htds) and a long 
form with 407 amino acids (5-ht4,_) (Gerald et al., 1994). Both these forms show similar pharmacology 
(Adham et ul., 1995) but the functional effects have not been established yet. 
3.3. Approach to Receptor Classification 
The knowledge accumulating from molecular biological work compels reconsideration of 
conceptual thinking behind receptor classification (Hoyer et al., 1994) not only in the case of 
serotonin, but for other neurotransmitters. The Nomenclature Committee of the Serotonin Club, 
which evolved the Bradley Classification of serotonin receptors (Bradley et al., 1986), once again 
assigned itself this task. After a brief report of its deliberations (Humphrey et al., 1993) a detailed 
version approved by the main IUPHAR Committee for Receptor Nomenclature has been published 
recently (Hoyer et al., 1994). 
The IUPHAR receptor nomenclature committee has advocated a number of criteria for receptor 
classification (Kenakin et al., 1992), and these have been extended by the Nomenclature Committee 
of the Serotonin Club (Hoyer et al., 1994). As shown in Table 2, these criteria fall into three categories: 
operational (selective agonists, selective antagonists and ligand binding affinities), structural 
(molecular structure of the receptor protein and, thus, the extent of homology) and transductional 
(intracellular eceptor-effecter coupling mechanism). Together, these provide a ‘finger-print’ basis 
for identifying distinct receptors. 
It is undeniably true that the structure of the receptor protein is the mark of true identity of the 
receptor. However, it is equally important to realize that substantial changes in the amino acid 
sequence may not affect (e.g. in the case of 5-HT,, and 5-HTID, receptors), while little alteration may 
cause vast changes in the operational characteristics of a receptor (e.g. in case of species homologous 
5-HTje and 5-HTloa receptors) (Hartig et al., 1992). 
Two other important recommendations have been made by Hoyer et al. (1994). Firstly, in keeping 
with the earlier suggestion (Kenakin et al., 1992), it has been advised to use lower case letters for 
recombinant receptors with little knowledge of operational characteristics (e.g. 5-ht, receptor) and 
upper case letters for reasonably well-characterized native receptors (e.g. 5-HTz receptor). Secondly, 
since not all necessary criteria, as outlined in Table 2, are always available, it is probably not possible 
to obtain a fully rationale classification scheme. Therefore, it is necessary to hold certain receptors 
provisionally in an ‘orphan’ category awaiting further characterization. 
3.4. The Present Classification of Serotonin Receptors 
Based on the general criteria mentioned in Table 2 and in keeping with the above 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































346 P. R. Saxena 
SEROTONIN RECEPTORS 
I 
)5-HT,,( (5-HT,,I I5-HT,,I r 5-htds 1 




Fig. 3. Subclassification of serotonin receptors. The receptors denoted in lower capital (e.g. S-ht,) 
are recombinant receptors, which are not fully characterized yet. The S-ht, and 5-htdL receptors 
are the short and long splice variants of the 5-ht, receptor. 
and 5-HT4 receptors), with certain recombinant (5-ht,,,, 5-htlD,, 5-ht,,, 5-htlF, 5-htds, 5-h& 5-ht,,, 
5-htjB, 5-h&, and 5-ht,) and ‘orphan’ receptors (Fig. 3). 
The specific operational, structural and transductional properties of the different serotonin 
receptors are shown in Table 3 (Hoyer et al., 1994). Structurally, all serotonin receptors, except 
the 5-HT3 receptor, which forms a part of cation channels, belong to the G-protein super- 
family and contain the characteristic seven transmembrane regions. All 5-HT, receptors are 
negatively coupled to adenylyl cyclase; all 5-HTz receptors, including the previously called 
5-HT,, receptor (hence renamed 5-HTzc), are coupled to protein kinase C via increased 
phosphoinositide breakdown, while the 5-HT+ 5-h& and 5-ht, receptors are positively linked to 
adenylyl cyclase. 
Except for the recombinant subtypes 5-htlE and 5-htlF (which have been placed in the group based 
on structural homology and transductional similarity), operationally all other 5-HT, receptors have 
high affinity for 5-carboxamidotryptamine asagonist and methiothepin as antagonist. It should be 
noted that such operational criteria also apply to the ‘orphan’ receptor mediating smooth muscle 
relaxation; indeed, it was known previously as the sumatriptan-insensitive 5-HT,-like (or 5-HTIU) 
receptor (Bradley et al., 1986; Saxena and Villalon, 1990a). However, in view of its positive coupling 
to adenylyl cyclase, this receptor, which may turn out to be identical to the recombinant 5-ht, receptor 
(Bard et af., 1993; Plassat et al., 1993), has been placed in the ‘orphan’ category. The 5-HTIA receptor 
has a high and selective agonist affinity for flesinoxan, 8-OH-DPAT and dipropyl-5-carboxami- 
dotryptamine, the 5-HT,, receptor has a high selective agonist affinity for CP 93,129, while both 
5-HT,, and 5-HTJike receptors have a relatively high affinity for sumatriptan. Selective antagonists 
have only recently been described for 5-HT,, (WAY 100135; Fletcher et al., 1993) and 5-HT,, (GR 
127935; Skingle et al., 1993; Clitherow et al., 1994) receptors, and undoubtedly, these will help in 
further characterization. With regard to the 5-HT,-like receptors, it is to be noted that their structure 
has not been elucidated yet (Table 3) and that these may be heterogeneous ( ee Saxena and Villalon, 
1990a; Hoyer et al., 1994). The operational characteristics of 5-HT,-like receptors resemble those 
of 5-htlo, and 5-ht,n, receptors, and it is possible that some 5-HT,-like receptors may turn out to be 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































350 P. R. Saxena 
The operational characteristics of 5-HT2 receptor subtypes are similar, but not identical; ketanserin 
seems to be much more potent at the 5-HTZA receptor than at the two other sub- 
types. In the case of the 5-HT3 and 5-HT4 receptors, potent and selective antagonists are now 
available. 
4. RESPONSES MEDIATED BY SEROTONIN RECEPTORS 
The functional responses associated with the different 5-HT, receptor subtypes are listed in Table 4. 
The 5-HT,, receptor stimulation is associated with behavioural changes and a centrally mediated 
hypotensive response. The 5-HTle receptor is present in the rodent CNS and seems primarily 
associated with decrease in transmitter elease. The same appears to be the case with 5-HT,n receptors 
in other mammals. In addition, it is suggested, though not definitely established yet, that stimulation 
of 5-ht,,, receptor decreases plasma extravasation following trigeminal nerve stimulation (Buzzi 
et al., 1991; Matsubara et al., 1991), while 5-ht ,nB receptors mediate contraction of cerebral arteries 
(Hamel et al., 1993). The contraction of cephalic arteries and arteriovenous anastomoses and 
inhibition of noradrenaline release from sympathetic nerve endings are mediated by 5-HT,-like 
receptors, but some 5-HT,-like receptors may be identical to the 5-HT,n receptors (Hoyer et al., 1994). 
Table 5 present examples of functional responses mediated by 5-HTz, 5-HT, and 5-HT4 receptors. 
The 5-HTzA receptor is ubiquitous and mediates mainly contraction of vascular and nonvascular 
smooth muscles, platelet aggregation and neuroexcitation. The 5-HTZB receptor has been located 
primarily in the rat and mouse stomach fundus and mediates contraction. The 5-HT,, receptor may 
regulate the amount and composition of the cerebrospinal fluid, as well as decrease locomotion and 
appetite. Undoubtedly, the 5-HT1 receptor is involved in vomiting resulting from radiation and 
anticancer drugs. In addition, stimulation of the 5-HTj receptor, which is a part of a cation channel, 
results in depolarization of peripheral and central neurons. Stimulation of the 5-HT4 receptor leads 
to decreases in K+ conductance in colliculi neurons and increases in EEG energy. Peripherally, 5-HT4 
receptors affect motility of the gastrointestinal tract and mediate increases in the porcine and human 
atria1 rate and contractility (Table 5). Interestingly, 5-HT4 receptors seem to be absent on porcine 
(Saxena et al., 1992; Schoemaker et al., 1992), as well as human (Jahnel et al., 1992; Schoemaker 
et al., 1993) ventricles. 
The structure of the recombinant 5-htsA, 5-ht,,, 5-hts and 5-ht, receptors is well-established, and 
these have been localized mainly in certain areas of the CNS, but the functions mediated are yet to 
be understood (Table 6). On the other hand, a number of serotonin receptors have been placed in 
a temporary ‘orphan’ category, since no structural data and only limited transductional and 
operational data are available yet (Table 6). 
5. THERAPEUTIC USES OF SEROTONIN RECEPTOR LIGANDS 
There are currently more than 70 pharmaceutical companies with interest in serotonergic 
drugs, and the leaders, in the rank order of the number of patents filed (and not the revenue 
earned), are shown in Fig. 4. This patent activity indicates that these companies expect to convert 
the new chemical entities into marketable products for therapeutic uses. The established, as well as 
some potential, therapeutic uses of serotonin receptor agonists and antagonists are listed in Table 7. 
5.1. Anxiety States 
The role of serotonin uptake inhibitors, as well as serotonin receptor ligands, in the treatment of 
anxiety states has been explored extensively (see Charney et al., 1990; Murphy et al., 1993). It appears 
that 5-HTIA receptor partial agonists uch as buspirone are clinically effective in generalized anxiety 
disorders and in anxiety associated with depression, but not in panic disorders. The effectiveness of
these drugs in obsessive anxiety disorders has been investigated so far in only one controlled trial 
(see Murphy et al., 1993). Animal experiments suggest that 5-HTIA receptors located in the 
hippocampus, thalamus, amygdala nd rapht nuclei are involved in the therapeutic effects of 5-HTIA 
receptor partial agonists in anxiety (Charney et al., 1990). Clinical results with the recently developed 
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Table 4. Examples of Functional Responses Thought to be Mediated by 5-HT, Receptors Subtypes’ 
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1 S-HT release 
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glutamate release 
1 NA release 
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Contraction 
1 S-HT release 





















1 NA release 
Dog 1 NA release 
Hoyer et al., 1986; Pazos et al., 1987; 
Radja et al., 1991 
Tricklebank, 1985; Lucki, 1992 
Giithert and Kolassa, 1990 
Middlemiss, 1986; Limberger et al., 1991 
Middlemiss, 1986; Engel et al., 1986; 
Limberger et al., 1991 
Giithert et al., 1986 
Saito et al., 1988; Matsubara et al., 1991 
Craig and Martin, 1993 
Middlemiss, 1986 
Harpel-Dupas et al., 1991 
Buzzi et al., 1991’ 
Schoeffter and Hoyer, 1990 
Hamel et al., 19933 
Leonhardt et al., 1989 
Beer et al., 1992; Miller and Teitler, 1992 
Adham et al., 1993; Lovenberg et al., 
1993b4 
Amlaiky et al., 19924 
Bax et al., 1992; Glusa and Mtiller- 
Schweinitzer, 1993 
Sumner and Humphrey, 1990; Mtiller- 
Schweinitzer, 1990; Sumner et al., 1992 
Martin and MacLennan, 1990; Van 
Heuven-Nolsen et al., 1990 
Hamel and Bouchard, 1991 
Parsons et al., 1989 
Connor et al., 1989b 
Van Charldorp et al., 1990 
Connor et al., 1989b 
Chang and Owman, 1989 
Saxena et al., 1986, 1989 
Connor et al., 1989a; Chester et al., 1990; 
Bax et al., 1993 
Tadipatri et al., 1991, 1992 
Sahin-Erdemli et al., 1991; Schoeffter 
and Sahin-Erdemli, 1992 
Moldering et al., 1990 
Fenuik et al., 1979; Watts et al., 1981 
‘Based on Saxena and Villalon (1990a) and Hoyer et al. (1994); %laimed to resemble 5-HT,,,, subtype; ‘claimed 
to resemble S-HTlos subtype; 4mentioned as 5-HTIeB or 5-HT&ike. 
Abbreviations-Ach, acetylcholine; AVAs, arteriovenous anastomoses; BP, arterial blood pressure; EDRF, 
endothelium-derived relaxant factor (probably nitric oxide); HR, heart rate; NA, noradrenaline. 
‘silent’ 5-HTIA receptor antagonists, such as WAY 100135 (Fletcher et al., 1993), are awaited with 
interest o settle the question whether an agonist or antagonist activity is important in the anti-anxiety 
effect. 
Some preliminary clinical trials suggest hat 5-HT2 and 5-HT, receptor antagonists may have a 
beneficial effect in generalized anxiety disorder patients (Murphy et al., 1993; Greenshaw, 1993). 
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Table 5. Examples of Functional Responses Thought to be Mediated by 5-HT2, LHT, and 5-HTs Receptors’ 
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Rat CNS areas 
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1 Motion, feeding 
Not well understood, 
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Pain and flare 
1 K+ conductance 
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r Rate and force 
t Heart rate 
t Force 
North and Uchimura, 1989 
Heninger et al., 1987 
Humphrey and Feniuk, 1987 
Bradley et al., 1986; Saxena and 
Villal&r, 1990a 
Bradley et al., 1986 
Bradley et al., 1986 
Gaddum and Picarelli, 1957; Bradley 
et al., 1986 
Bradley et al., 1986 
Foguet et al., 1992; Kursar et al., 1992 
Foguet et al., 1992 
Pazos et al., 1984; Yagalofand Hartig, 
1985 
Curzon and Kennett, 1990 
Kilpatrick et al., 1987, 1990; Weber 
et al., 1989; Hamon et al., 1989; 
Laporte et al., 1992 
Fozard, 1990; Saxena and Villalon, 
1990a 
Fozard, 1990; Saxena and Villalon, 
1990a 
Fozard, 1990; Saxena and Villalon, 
1990a 
Orwin and Fozard, 1986 
Demuis et al., 1988; Fagni et al., 1992 
Boddeke and Kalkman, 1990 
Tonini et al., 1989 
Craig et al., 1990; Buchheit and Buhl, 
1991 
Elswood et al., 1991; Wardle and 
Sanger, 1993 
Tuladhar et al., 1991, 1992 
Baxter et al., 1991a; Reeves et al., 
1991; Ford et al., 1992 
Baxter et al., 1991b; Tam et al., 1992; 
McLean et al., 1993 
Burleigh and Brown, 1993 
Waiker et al., 1994 
Corsi et al., 1991 
Lefebvre et al., 1993 
Kaumann, 1990* 
Saxena, 1986; Villalon et al., 1990, 
1991’ 
Kaumann er al., 1990, 1991) 
‘Based on Hoyer et al. (1994); 2porcine ventricles lack S-HT4 receptors (Saxena et al., 1992; Schoemaker et al., 
1992); )human left ventricles lack S-HT., receptors (Jahnel et al., 1992; Schoemaker et al., 1993). 
Abbreviations-CSF, cerebrospinal fluid; EPSP, excitatory postsynaptic potential. 
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Table 6. Examples of Functional Responses Thought to be Mediated by other Serotonin Receptors 
Species Tissues Responses References 
5-HT,,s 
Mouse/rat CNS areas Unknown Plassat et al., 1992; Matthes et al., 1993; 
Erlander et al., 1993 
5-hts 
Rat Striatum Unknown Monsma et al., 1993; Ruat et al., 1993a 
5-ht, 
Rat Hypothalamus/thalamus Unknown Lovenberg et al., 1993a 
Rat Cerebellum, heart, gut Unknown Plassat et al., 1993 
‘Orphan’ receptors 
‘Orphan’ (Vascular smooth muscle) 
Several Vascular smooth muscle Relaxation Bradley et al., 1986; Saxena and Villalon, 
1990a 
Pig Vena cava Relaxation Trevethick et al., 1986; Sumner, 1991 
Cat Saphenous vein Relaxation Humphrey and Fenuik, 1987 
Rabbit Jugular vein Relaxation Martin et al., 1987 
Pig Carotid arterioles Relaxation Saxena et al., 1986, 1989 
Cat Heart 7 Heart rate Saxena et al., 1985; Connor et al., 1986 
‘Orphan’ (Vascular endothelium) 
Several Vascular endothelium EDRF release Saxena and Villalon, 1990a 
Rabbit Jugular vein Relaxation Leff et al., 1987; Martin et al., 1987 
Pig Vena cava Relaxation Sumner, 1991 
Pig Pulmonary artery Relaxation Glusa, 1992 
Chick Jugular vein Relaxation Imaizumi et al., 1984 
‘Orphan’ (Rat motoneuron) 
Rat Spinal motoneuron Depolarization Connell and Wallis, 1989 
‘Orphan’ (Sympathetic neurons) 
Pig Coronary artery 1 NA release Molderings et al., 1989 
‘Orphan’ (S-HT,r) 
Several Enteric neurons Slow depolarization, Gershon et al., 1991; Frieling et al., 1991 
1 Ach release 
Abbreviations-Ach, acetylcholine; EDRF, endothelium-derived relaxant factor (probably nitric oxide); NA, 
noradrenaline. 
Based on Saxena and Villalbn (1990a) and Hoyer et al. (1994). 
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Table I. Some Therapeutic uses of Drugs Acting at Serotonin Receptors 
Disease Status References 





_5-HT,, receptor antagonists 
WAY 100135 Anxiety 





5-HTjO receptor antagonists 
GR127935 Depression 
S-HT2, receptor antagonists 
Ketanserin’ Hypertension 
Ritanserin and Anxiety, psychosis, 
Risperidone Sleep disorders 
Methysergide’ Migraine 
Pizotifen2 Migraine 
5-HT, receptor antagonists 
SB 200646 Feeding disorders 
SB 200646 Migraine 
S-HT3 receptor antagonists 
Ondansetron Radiation vomiting 
Granisetron Radiation vomiting 
Tropisetron Radiation vomiting 
Ondansetron Psychosis 
Tropisetron Migraine 
Alosetron Drug craving 
Alosetron Schizophrenia, IBS 
Alosetron Memory impairment 
5-HT, receptor agonists 
Cisapride’ Gastric motility 
Renzapride Gastric motility 
SC 49518 Gastric motility 
5-HT4 receptor antagonists 
GR 125487 IBS 
Marketed 
Clinical phase 3 




Clinical phase 3 
Clinical phase 2 
Clinical phase 2 
Preclinical 
Marketed McGourty et al., 1985; Saxena and Wouters, 
1990 
Clinical phase 3 Westernberg and Dan Boer, 1989; Castelao 
et al., 1989 
Marketed Saxena and Den Boer, 1991 






Clinical phase 2 
Ineffective 
Preclinical 
Clinical phase 2 
Clinical phase 2 
Marketed 
Clinical phase 3 
Preclinical 
Preclinical Oxford, 1993 
Kaumann and Sanders, 1994 SB 207710 Cardiac arrhythmias Preclinical 
‘cl-Adrenoceptor antagonist activity is apparently more important; 2other actions are involved; ‘other 
properties probably are also involved. 
Abbreviations-IBS, irritable bowel syndrome. 
Compounds--BW31 lC, N,N-dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol-3-yl]-ethylamine; 
GR 125487, [l-[2-[(methylsulphonyl)~no]ethyl]4pi~~dinyl]methyl-5-fluoro-2-methoxy-1H-indole-3-car- 
boxylate hydrochloride; GR 127935, N-[methoxy-3-(4-methyl-1-piperazinyl)-phenyl]-2’-methyl-4’-(5 methyl 
1,2,4-oxadiazol-3-yl) [l,l,-biphenyll-Qcarboxamide; MK-462, NJ,-dimethyl-Z[5-( 1,2,4-triazol-l-yl-methyl)- 
lH-indol3-yl]ethylamine; SB 200646, N-(l-methyl-S-indoyl)-N-(3-pyridol urea hydrochloride) (Forbes et al., 
1993); SB 207710, [( 1-butyl-4-piperidinylmethyl)-8-amino-7-iodo- 1.4~benzodioxan-5-carboxylate]; SC 49518, 
N-[exo-(hexahydro-lH-pyrrolizine-l-yl]-2-methoxy-4-amino-5chlorobenzamide hydrochloride; WAY 
100135, N-tert-butyl-3-(4-[2-methoxyphenyl]pipern-l-yl)-2-phenylpropanamide ihydrochloride. 
Goldberg and Finnerty, 1979; Goa and 
Ward, 1986 
Glasser, 1988 
Costello et al., 1991; Pecknold et al., 1993 
Ramage, 1986; Kolassa et al., 1993; Saxena 
and Villalon, 1990b 
Fletcher et al., 1993 
Ferrari and Saxena, 1993; Saxena and 
Tfelt-Hansen, 1993; Welch, 1993 
Connor et al., 1993; Perren et al., 1993 
Robertson et al., 1991 
Beer et al., 1994; Shepheard et al., 1994 
Skingle et al., 1993 
Kennett, 1993 
Fozard and Gray, 1989; Kennett, 1993 
Grunberg et ul., 1990; Marty et al., 1990 
Chevallier et al., 1990 
Dogliotti et al., 1990 
Costa11 et al., 1993 
Ferrari, 1991; Ferrari et al., 1991 
Hagan et al., 1993 
Hagan et al., 1993 
Preston et al., 1992 
Briejer et al., 1993 
King et al., 1993b 
Gullikson et al., 1993 
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However, the evidence so far is far from compelling, and the results of larger placebo-controlled 
clinical trials are awaited. 
5.2. Other Central Nervous System Diseases 
Drugs acting on serotonin receptors can have potential use in several other CNS diseases, like 
depression, schizophrenia, memory impairment, sleep disorders and substance abuse (see Table 7). 
Since 5-HT,n receptors have been located at serotonergic nerves and can inhibit the transmitter 
release, antagonists at these autoreceptors may increase serotonin release and, thus, have 
antidepressant activity. The 5-HTz receptor antagonists, ritanserin and risperidone, which also blocks 
dopamine receptors, are being explored for use in psychosis and sleep disorders (Castelao et al., 1989; 
Westenberg and Den Boer, 1989; Min et al., 1993). Lastly, clinical investigations with 5-HTI receptor 
antagonists are being performed in schizophrenia, substance abuse and memory impairment (see 
Preston et al., 1992; Costa11 et al., 1993; Greenshaw, 1993; Hagan et al., 1993). Results of more 
extensive and controlled clinical trials are awaited with great interest. 
5.3. Migraine 
A large number of studies has shown conclusively that sumatriptan, an agonist at 5-HT,-like 
receptors, is effective in aborting migraine attacks (see Ferrari and Saxena, 1993; Saxena and 
Tfelt-Hansen, 1993; Welch, 1993). The success of this drug, both in a clinical and economic sense, 
has prompted a large number of pharmaceutical companies-Bristol-Myers Squibb (Smith et al., 
1992), Glaxo (Connor et al., 1993; Johnson and North 1993; Perren et al., 1993) Merck Sharp 
and Dohme (Baker et al., 1994), Merrel Dow (McDonald et al., 1992) Wellcome Foundation 
(King et al., 1993a) and others-to try to develop novel 5-HT,-like receptor agonists. In particular, 
the efforts are directed to make more lipid-soluble and selective compounds to improve oral 
bioavailability and avoid coronary artery vasoconstriction. High lipid solubility can turn out to be 
a double-edged weapon, since such molecules, unlike sumatriptan (Dallas et al., 1989). would be 
expected to readily cross the blood-brain barrier and may then be associated with a higher incidence 
of unwanted effects. For example, in the case of compounds with a similar receptor profile as 
sumatriptan, the 5-HT,, receptor agonism may lead to hypotension and bradycardia (see Saxena and 
Villalon, 1990a,b). 
It is argued sometimes that sumatriptan owes its therapeutic activity solely to a presynaptic action, 
which inhibits neuropeptide releases and, therefore, ‘neurogenic’ inflammation (Moskowitz, 1993). 
Though this view is not shared universally (see Saxena and Ferrari, 1989; Humphrey and Feniuk, 
1991; Ferrari and Saxena, 1993; Saxena and Tfelt-Hansen, 1993), it is of interest to note that NK, 
receptor antagonists, such as RP 67580 (Shepheard et al., 1993) have been found far more potent 
than 5-HTle:n receptor agonists (CP 93,129 and sumatriptan) in blocking neurogenic plasma 
extravasation following trigeminal ganglion stimulation. Should such compounds prove effective as 
antimigraine agents, the involvement of ‘neurogenic’ inflammation in migraine will have a stronger 
footing, though it will not be regarded as an argument against the involvement of vascular 
mechanisms (Saxena and Ferrari, 1989; Humphrey and Feniuk, 1991; Ferrari and Saxena, 1993; 
Saxena and Tfelt-Hansen, 1993). 
Some antimigraine drugs are potent antagonists at 5-HT,, receptors (methysergide. pizotifen, 
ergotamine, dihydroergotamine), but many other such agents (ketanserin, ritanserin, cypro- 
heptadine, mianserin, methiothepin, metergoline, sergolexole, ICI 169,369) have not been found of 
much use in migraine therapy (Winther, 1985; Davies and Steiner, 1990; Tfelt-Hansen and Pedersen, 
1992; Tfelt-Hansen and Saxena, 1993). It seems, therefore, that additional properties of these 
antimigraine drugs, for example, the vasoconstriction in the extracerebral cephalic circulation with 
methysergide, ergotamine and dihydroergotamine (partly via 5-HT,-like receptors) and the 
antidepressant action with pizotifen, may be involved in their therapeutic action (Saxena and Den 
Boer, 1991). Based mainly on the ability of a 5-HT,e receptor agonist, m-chloro-phenyl piperazine, 
to elicit migraine-like headaches in some patients and the ability of drugs such as mianserin to block 
this receptor, it has been advocated that 5-HTZc receptor antagonism is important for antimigraine 
action (Fozard and Gray, 1989; Fozard, 1992; Kennett, 1993). It should be noted, however, that 
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m-chloro-phenyl-piperazine is not a selective agent and drugs that block the 5-HTzc receptor (e.g. 
mianserin, sergolexole) are not particularly effective against migrainous headaches. Moreover, rather 
than being antagonists, the antimigraine drugs ergotamine and dihydroergotamine behave as potent 
agonists at the 5-HTlc receptor (Brown et al., 1991). 
Despite the fact that many 5-HT3 receptor antagonists are known for several years and three of 
them (ondansetron, granisetron and tropisetron) are in clinical use for the treatment of vomiting 
induced by anticancer drugs, only two such drugs (MDL 72222 and granisetron) have been reported 
to be effective in migraine (Loisy et al., 1985; Couturier et al., 1991). Though MDL 72222 was studied 
in a double-blind, placebo-controlled manner (Loisy et al., 1985), this study has been flawed on 
several grounds (Ferrari, 1991; Ferrari et al., 1991). Granisetron was evaluated in an open study on 
six patients (Couturier et al., 1991) and, despite encouraging results, this study was discontinued, 
according to the investigators “for extraneous reasons”. On the other hand, carefully designed and 
extensive investigations with tropisetron, both as acute and prophylactic migraine therapy, were 
largely negative (Ferrari, 1991; Ferrari et al., 1991). Since no other positive results are known with 
any of the 5-HT, receptor antagonists, it must be concluded that this receptor does not play a major 
role in migraine. 
The above analysis strongly suggests that within the bounds of serotonergic mechanisms, 
the antimigraine action mainly depends upon an agonist action at the 5-HT,-like receptor subtype 
that mediates cephalovascular constriction (Saxena et al., 1993). 
5.4. Vomiting 
Nausea and vomiting are extremely unpleasant side effects of anticancer drugs, and the dopamine 
D2 receptor antagonists are not very effective as antiemetic agents. Following the report that high 
doses of metoclopramide, which also blocks 5-HT3 receptors (Bradley et al., 1986; Fozard, 1990) 
can prevent cisplatin-induced vomiting in cancer patients (Gralla et al., 1981), it was realized that 
5-HT, receptor blockade may play an important role in vomiting (Miner and Sanger, 1986). Indeed, 
ondansetron (Grunberg et al., 1990; Marty et al., 1990) granisetron (Chevallier et al., 1990) and 
tropisetron (Dogliotti et al., 1990) have all been shown to successfully suppress the acute phase of 
vomiting caused by cisplatin; unfortunately, the delayed phase is not much affected (see Wells et al., 
1993). The 5-HT3 receptor antagonists are selectively effective against vomiting following cancer 
chemotherapy, radiation exposure or general anaesthesia; these drugs do not prevent vomiting due 
to other causes, such as motion sickness. 
The mechanism of antiemetic action of 5-HTs receptor antagonists appears to be at the level of 
sensory vagal nerve terminals in the gastrointestinal mucosa, with a possible additional effect at the 
chemoreceptor t igger zone, where 5-HT3 receptors have also been localized (Kilpatrick et al., 1987; 
Wells et al., 1993). Microdialysis measurements have clearly shown that cisplatin increases erotonin 
levels in the ileum, as well as the blood, and such increases are accompanied by vomiting episodes 
(Fukui et al., 1993). 
5.5. Hypertension 
Both urapidil (5-HTIA receptor agonist) and ketanserin (5-HTzA receptor antagonist) have been 
approved for the treatment of hypertension. Indeed, it is claimed that these drugs decrease blood 
pressure by stimulating 5-HT,, receptors located centrally in the nucleus tractus solitarus (urapidil) 
or by blocking 5-HT,, receptors mediating peripheral vasoconstriction (ketanserin). However, 
as discussed in detail elsewhere (Saxena and Wouters, 1990) it does not appear that such effects are 
involved to a significant degree in the clinical effects of these drugs; both urapidil and ketan- 
serin have a potent a,-adrenoceptor antagonist activity, which can adequately explain the anti- 
hypertensive ffect (see Saxena and Villalon, 1990b). 
5.6. Gastric Motility Disorders 
It is well known that high concentrations of serotonin are present in the gastrointestinal tract, 
where it appears to play an important physiological role in the peristaltic movements (see Gershon 
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et al., 1991). Although some progress has been made towards delineation of the nature and function 
of serotonin receptors in the gastrointestinal tract of several animal species (Dhasmana et al., 1993), 
the knowledge with regard to the human gut is still scant (Talley, 1992; Tam et al., 1992; McLean 
et al., 1993). However, 5-HT3 and 5-HT4 receptor antagonists are being explored for therapeutic use 
in irritable bowel syndrome (Prior and Reed, 1993) since these drugs slow colonic transit in healthy 
volunteers (Gore et al., 1990; Talley et al., 1990). 
The 5-HT4 receptor agonists eem to have a prokinetic effect (Briejer et al., 1993; Gullikson et al., 
1993; King et al., 1993b; Stacher et al., 1993), and their use in reflux oesophagitis (Geldof et al., 1993) 
and idiopathic (Corinaldesi, 1993) and diabetic (Kawagishi et al., 1993) gastroparesis is being 
advocated. 
5.7. Pain 
Recent preclinical studies uggest that 5-HT is involved in the mediation of pain, but it has multiple 
and opposing effects, which depend upon the location and the type of receptor involved (Greenshaw, 
1993). 
Within the superficial dorsal horn of the spinal cord, a dense band of 5-HT, receptors has been 
located on capsaicin-sensitive primary afferent nerve terminals. These 5-HT, receptors mediate an 
antinociceptive effect against intrathecal application of substance P and N-methyl-D-aspartate, 
possibly via y-aminobutyric acid release (Alhaider et al., 1991). In contrast, peripheral 5-HTj 
receptors mediate an algesic response following topical application of serotonin on blister base in 
humans (Richardson et al., 1985; Fozard, 1990). 
The nociceptive response to i.v. serotonin may be mediated by both 5-HTz and 5-HT3 receptors 
located on capsaicin-sensitive vagal nerve afferents and, therefore, a combined use of 5-HT? and 
5-HT, receptor antagonists has been suggested for the relief of pain in angina pectoris and other 
peripheral vascular disorders (Mellor et al., 1992). Interestingly, both 5-HT, and 5-HT? receptors 
mediate human coronary artery constriction induced by 5-HT (Connor et al., 1989a; Chester et al., 
1990; Bax et al., 1993), as well as platelets, even after cyclooxygenase inhibition with aspirin (Bax 
et al., 1994). Thus, it is advocated that a combined use of 5-HT, and 5-HTz receptor antagonists may 
have some role in the treatment of angina pectoris (Bax et al., 1994). 
5.8. Cardiac Disorders 
Increases in the rate and contractility in the human atrium are mediated by 5-HT4 receptors (see 
Table 5). Serotonin can induce arrhythmias in the human isolated atrium and, therefore, 5-HT4 
receptor antagonists could be useful in the treatment of cardiac arrhythmias (Kaumann and Sanders, 
1994). However, it is not established yet if serotonin plays any role in the pathogenesis of cardiac 
arrhythmias. 
The increase in atria1 contractility by 5-HT4 receptor agonists indicated that such drugs may 
have application in the therapy of heart failure. Any such hope has now been dashed, as recent 
investigations indicate that 5-HT, receptors are not present on human ventricles (Jahnel et al., 1992; 
Schoemaker et al., 1993). 
6. CLOSING REMARKS 
During the last decade, research in the field of serotonin has been boosted by the availability of 
potent and selective drug tools. These drug tools and increasing understanding of the transduction 
mechanisms, as well as the structure of the receptor protein, have enabled the characterization and 
nomenclature of serotonin receptors in a more meaningful way. Thus, four main classes with several 
subtypes (5-HT1, 5-HTz, 5-HT3, 5-HT.,), as well as some recombinant (e.g. 5-ht,,, 5-htse, 5-ht,, 5-ht,; 
note the use of lower case alphabets) and ‘orphan’ serotonin receptors, have been recognized. The 
suggestions made by the Nomenclature Committee of the Serotonin Club and the criteria used in 
classifying serotonin receptors undoubtedly will be helpful to other groups involved in the 
classification of pharmacological receptors. 
358 P. R. Saxena 
The molecular cloning and expression of a growing number of serotonin receptors in host cells 
now offers the possibility to screen new molecules relatively easily in order to recognize more selective 
ligands. However, this development poses new challenges. Obviously, one of the challenges involves 
the understanding of the precise function of the recombinant receptors at the various anatomical 
locations. Secondly, it may be asked why should there be so many serotonin receptor subtypes in 
the body. Is it that each receptor subtype mediates a specific function, or is it that more than one 
receptor subtype mediates the same function, perhaps under different circumstances, thus providing 
‘receptor backup’? The answers will dictate the strategy with regard to the degree of selectivity in 
developing therapeutically relevant molecules. 
The responses mediated via many serotonin receptors are now well understood, and this, in 
turn, has resulted in the development and use of serotonergic drugs in the therapy of several diseases, 
including anxiety and migraine. Given the pace with which new knowledge is emerging, therapeutic 
potentials of serotonin-based rugs will undoubtedly be exploited further. The availability of 
newer and more selective serotonin iigands will help us better define the role of serotonin and 
its receptors in physiological processes and pathophysiological mechanisms. This knowledge, in turn, 
will provide access to better drugs for treatment of human ailments more efficiently. Thus, the future 
of serotonin research looks as bright as ever. 
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